[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-diseases-infectious\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-diseases-infectious":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,99],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100403652","multi-vendor-multi-site-novel-accelerated-mri-relaxometry-100403652",false,"NCT04536103","Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry","MVMS_MRI","Inclusion Criteria:\n\nGroup 1\n\n1\\. Age \\> 18\n\nGroup 2\n\n1\\. Age 18-50\n\nGroup 3\n\n1. Age 18-50\n2. Sustain an acute full ACL tear in one knee; the contralateral knee uninjured\n3. Undergo ACL reconstructions and standard rehabilitation\n\nGroup 4\n\n1\\. Age 18-50\n\nExclusion Criteria:\n\nGroup 1\n\n1. Contraindication to MRI such as severe claustrophobia and implanted devices such as neurostimulators, pacemakers, aneurysm clips etc.\n2. Pregnancy.\n\nGroup 2\n\n1. Contraindication to MRI such as severe claustrophobia and implanted devices such as neurostimulators, pacemakers, aneurysm clips etc.\n2. Pregnancy.\n3. History of osteoarthritis and inflammatory arthritis\n4. Previous injury and\u002For surgery on either knee\n\nGroup 3\n\n1. Contraindication to MRI such as severe claustrophobia and implanted devices such as neurostimulators, pacemakers, aneurysm clips etc.\n2. Pregnancy.\n3. Inability to undergo standard pre- and post-injury\u002Foperative rehabilitation\n\nGroup 4\n\n1. Contraindication to MRI such as severe claustrophobia and implanted devices such as neurostimulators, pacemakers, aneurysm clips etc.\n2. Pregnancy.\n3. History of osteoarthritis and inflammatory arthritis\n4. Previous injury and\u002For surgery on either knee","ALL","18 Years","50 Years",{"count":20,"type":21},88,"ESTIMATED","OBSERVATIONAL","Currently the diagnosis of OA is based on radiographs and clinical findings, which is limited to detecting late-stage disease. There is a pressing, unmet clinical need for robust assessment of early changes in cartilage health. Towards this goal, extensive efforts are ongoing to develop quantitative MRI for cartilage matrix analysis. MR T1ρ and T2 relaxation times have shown to be promising imaging biomarkers for early cartilage degeneration and prediction of disease progression. However, many challenges remain to clinically applying these techniques, including lack of standardized acquisition and quantification methods, and long acquisition times. The study aims to develop novel, fast and reproducible MR T1ρ and T2 relaxation time imaging methods on MR systems from multiple vendors and establish a platform for standardization and cross validation of these measures as a tool for clinical trials using such techniques. Following method validation, patients at risk for osteoarthritis will be tested.",[25,26,27,28,29,30],"Bone Diseases, Infectious","Musculoskeletal Diseases","Joint Diseases","Osteoarthritis","ACL Tear","Cartilage Degeneration","RECRUITING","2026-02-24",{"date":34,"type":35},"2026-02-27","ACTUAL",{"date":37,"type":35},"2022-04-01",{"date":39,"type":21},"2026-12-28",{"name":41,"class":42},"Xiaojuan Li","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":54,"conditions":55,"keywords":71,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":98},"100284234","fosfomycin-iv-for-treatment-of-severely-infected-patients-100284234","NCT02979951","Fosfomycin I.v. for Treatment of Severely Infected Patients","An International, Multicentre, Non-comparative, Non-interventional, Prospective Clinical Registry to Evaluate the Clinical Outcome and Safety of the Treatment of Severely Infected Patients with Fosfomycin I.v.","FORTRESS","Inclusion Criteria:\n\n* Male or female patients aged ≥ 18 years\n* Treatment with fosfomycin according to the (national) Summary of Product Characteristics (SmPC) of fosfomycin i.v.\n* Patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis\u002Fcentral nervous system infection, bacteraemia\u002Fsepsis, skin and soft tissue infection, endocarditis or other infection, each as far as covered by the respective nationally relevant SmPC\n* Written informed consent of the participant (or person in charge in case of patients incapable of giving consent)\n\nExclusion Criteria:\n\n* Previous documentation of the patient in the present study\n* Patients participating in an interventional clinical trial\n* Patients with known hypersensitivity to fosfomycin or any of the excipients\n* Terminally ill patients\n* Patients with \"do not resuscitate order\"\n* Palliative treatment approach\n* Failure of \\> 3 of the following organ systems: respiratory system, nervous system, cardiovascular system, liver, coagulation, kidney\n* Manifest Human Immunodeficiency Virus (HIV) disease (Acquired Immunodeficiency Syndrome, AIDS)\n* Fosfomycin treatment as 4th line treatment or at later stage\n* Patients with involvement of fungi or mycobacteria in the targeted infection",{"count":53,"type":21},1000,"The purpose of this European, multicentric, prospective, non-interventional study is to document and evaluate the efficacy and safety of the treatment of severely infected patients with intravenously administered fosfomycin, including patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis\u002Fcentral nervous system infection, bacteraemia\u002Fsepsis, skin and soft tissue infection, endocarditis or other infections, each as far as covered by the respective nationally relevant SmPC.",[56,25,57,58,59,60,61,62,63,64,65,66,67,68,69,70],"Bacterial Infections","Osteomyelitis","Central Nervous System Bacterial Infections","Meningitis, Bacterial","Encephalitis","Brain Abscess","Urinary Tract Infections","Respiratory Tract Infections","Pneumonia, Bacterial","Skin Diseases, Bacterial","Soft Tissue Infections","Intraabdominal Infections","Sepsis","Bacteremia","Endocarditis, Bacterial",[72,73,74,75,76,77,78,79,80,81,56,82,83,25,57,58,59,60,61,62,63,64,65,66,67,68,69,70,84,85,86,87],"Observational Study","Non-Interventional Study","Registries","Prospective","Monitored","Multicentric","International","Fosfomycin","Infectofos","Fomicyt","Gram-Negative Bacterial Infections","Gram-Positive Bacterial Infections","Treatment Outcome","Clinical Efficacy","Microbiological Efficacy","Safety","2024-09-27",{"date":90,"type":35},"2024-10-01",{"date":92,"type":4},"2016-12",{"date":94,"type":21},"2030-12",{"name":96,"class":97},"Infectopharm Arzneimittel GmbH","INDUSTRY",50,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":109,"conditions":110,"keywords":123,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":43},"100486132","gene-expression-profiles-in-spinal-tuberculosis-100486132","NCT05610098","Gene Expression Profiles in Spinal Tuberculosis.","Comparing Gene Expression Profiles of Adults With Isolated Spinal TB to Disseminated Spinal TB Identified by 18FDG-PET\u002FCT at Time of Diagnosis, 6-and 12-months Follow-up","SpinalTBX","Inclusion Criteria\n\n1. Participant has completed the written informed consent process prior to undergoing any clinical evaluations and willing to undergo HIV testing\n2. TB spine based on clinical and radiological criteria\n3. Age 18 or older with a body weight of at least 40 kg body weight\n4. Able and willing to return to follow-up\n5. Willing to have samples, including DNA including RNA extraction, stored\n6. Willing to consistently practice a highly reliable method of pregnancy prevention\n\nExclusion Criteria\n\n1. Pregnancy or active desire to become pregnant within the next 6 months.\n2. Uncontrolled diabetes (HbA1c ≥ 6.5% \u002F random glucose concentration ≥11.1 mmol\u002Fl, fasting plasma glucose ≥ 7.0 mmol\u002Fl)\n3. Alcohol and substance abuse which might interfere with medication adherence during the trial\n4. Positive SARS-CoV-2 PCR in the past 4 weeks\n5. Suspicion of malignancy on MRI or known malignancy\n6. Suspicion of inflammatory disease and other rheumatological conditions\n7. Any person for whom the physician feels this study is not appropriate",{"count":108,"type":21},100,"Tuberculosis (TB) is one of the top ten causes of death worldwide with approximately 10 million cases globally and 1.2 million deaths. Sub-Saharan Africa carries the highest burden of TB. South Africa has one of the highest HIV and TB rates worldwide with an HIV prevalence rate in adults of 19% and a TB case notification rate of 615\u002F100,000 in 2019. Over many years, focus has been paid to pulmonary TB and extrapulmonary TB (EPTB) has received only little attention even though it accounts for almost a quatre of all TB cases. The diagnosis of EPTB remains challenging simply because sample collection requires invasive procedures in the absence of a blood-based diagnostic test. Spinal TB (spondylitis or spondylodiscitis caused by Mycobacterium tuberculosis) - often known as Pott's disease - accounts for up to 10% of EPTB and affects young children, people with HIV-coinfection and elderly, and often leads to lifelong debilitating disease due to devastating deformation of the spine and compression of neural structures. Little is known with regards to the extent of disease and isolated TB spine as well as a disseminated form of TB spine have been described. The latter presents with a spinal manifestation plus disseminations to other organs such as the lungs, pleura, lymph nodes, the GIT or urinary tract or even the brain.\n\nIn the Spinal TB X cohort, the investigators aim to describe the clinical phenotype of spinal TB using whole body PET\u002FCT and identify a specific gene expression profile for the different stages of dissemination and compare findings to previously described signatures for latent and active pulmonary TB. A blood-based test for spinal TB would lead to earlier diagnosis and treatment in all settings globally and improve treatment outcome of this devastating disease.",[111,112,113,114,115,25,26,116,117,118,119,120,121,122],"Tuberculosis, Spinal","Tuberculosis, Osteoarticular","Tuberculosis","Mycobacterium Infections","Infections","Spinal Disease","Spondylitis","Spondylitis; Tuberculosis (Manifestation)","Spondylodiscitis","Positron-Emission Tomography","Diagnostic Imaging","Diagnostic Techniques and Procedures",[124,125,126,127],"Spinal TB","tuberculous spondylodiscitis","FDG-PET\u002FCT","POC","2024-08-22",{"date":130,"type":35},"2024-08-23",{"date":132,"type":35},"2022-10-25",{"date":134,"type":21},"2026-12-31",{"name":136,"class":42},"University of Cape Town"]